Ipsen in the United Kingdom
Dating back to 1990, the Wrexham facility is dedicated to the production of biological compounds. Dysport® is produced at Wrexham. In addition to the manufacturing of existing drugs and product development, Wrexham also serves as the logistics platform for the UK.
Ipsen’s site in Slough houses a number of the Group’s R&D activities (clinical development, regulatory affairs, pharmacovigilance, etc.). Slough is also the Group’s commercial affiliate in the UK.
This R&D center has an expertise in natural and modified recombinant botulinum toxins, and in targeted secretion inhibitors or retargeted molecules.
27 September 2016 - Paris (France)
Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the…